Legato Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Legato Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.13M	Sell	36,641 -397	-1%	-$18.3K	0.19%	162
2025 Q4	$1.66M	Buy	37,038 +22,829	+161%	+$959K	0.14%	222
2025 Q3	$570K	Buy	14,209 +4,587	+48%	+$162K	0.06%	427
2025 Q2	$301K	Hold	9,622	–	–	0.04%	498
2025 Q1	$323K	Buy	+9,622	New	+$365K	0.04%	478
2024 Q2	–	Sell	-16,085	Closed	-$692K	–	630
2024 Q1	$692K	Buy	16,085 +4,248	+36%	+$195K	0.08%	361
2023 Q4	$545K	Buy	11,837 +155	+1%	+$5.48K	0.07%	398
2023 Q3	$399K	Sell	11,682 -628	-5%	-$23.5K	0.06%	441
2023 Q2	$474K	Buy	+12,310	New	+$489K	0.06%	432

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Legato Capital Management's XENE Position: Q1 2026 in Review

Legato Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 1.1% in Q1 2026, selling an estimated $18.3K and leaving 36,641 shares worth $2.13M. The position accounts for 0.19% of the portfolio, ranked #162.

Legato Capital Management first reported a position in XENE in Q2 2023 and has held it in 9 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Legato Capital Management held 36,641 shares of Xenon Pharmaceuticals worth $2.13M as of Q1 2026.
Legato Capital Management sold 397 Xenon Pharmaceuticals shares in Q1 2026, an estimated $18.3K.
Xenon Pharmaceuticals made up 0.19% of Legato Capital Management's portfolio in Q1 2026, its #162 holding.
Legato Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.